Drug intelligence / Profile preview

MG-GDX19

Development stage: Preclinical
Lead developer: MEPSGEN
Modality: Nanoparticles → Drug Delivery Systems

Overview

MG-GDX19 is a nanomedicine candidate being developed by MEPSGEN for the treatment of medulloblastoma. It is part of the company's MG-X_Nanomedicine pipeline, which utilizes a proprietary biomimetic nanoparticle platform designed to facilitate the delivery of therapeutic agents across the blood-brain barrier (BBB). The drug is currently in the discovery stage of development. MEPSGEN leverages its specialized microvortex technology (MST-X) and NanoCalibur synthesis system to produce these standardized, scalable nanocarriers, aiming to improve therapeutic efficacy and reduce systemic toxicity for patients with brain tumors.

Other names: MG-GDX19-MEPSGEN-nanomedicine-MedulloblastomaMG-GDX-19-MEPSGEN-nanomedicine-MedulloblastomaMG-GDX 19-MEPSGEN-nanomedicine-Medulloblastoma

Beyond the preview

Go deeper on MG-GDX19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG-GDX19.

Explore the full profile